FDA/Industry Statistics Workshop 2005 Parallel Session 6: Vaccine Trials 10:10 am – 11:30 am, Sept. 16, 2005.

Slides:

Advertisements

Similar presentations

Two dose Q-HPV Vaccine Study

Advertisements

Non-randomized Medical Device Clinical Studies: A Regulatory Perspective Sep. 16, 2005 Lilly Yue, Ph.D.* CDRH, FDA, Rockville MD * No official support.

Patient Selection Markers in Drug Development Programs

Drugs vs. Devices Jeng Mah & Gosford A Sawyerr Sept 16, 2005.

Non-randomized studies: Studies with historical controls and the use of Objective Performance Criteria (OPCs) Jeff Cerkvenik Statistics Manager Medtronic,

The Vaccine Adverse Event Reporting System: A Tool for Safety and Surveillance Jane Woo, MD, MPH Vaccine Safety Branch Division of Epidemiology Office.

What Is the Role for Analyses of Administrative Data in Assessing Drug Safety in Post-Market Commitment (PMC) Studies? Cathy W. Critchlow, PhD Global Epidemiology,

1 Superior Safety in Noninferiority Trials David R. Bristol To appear in Biometrical Journal, 2005.

The Application of Propensity Score Analysis to Non-randomized Medical Device Clinical Studies: A Regulatory Perspective Lilly Yue, Ph.D.* CDRH, FDA,

Statistical Issues and Challenges in Combination Vaccines

1 FDA Industry Workshop Statistics in the FDA & Industry The Future David L DeMets, PhD Department of Biostatistics & Medical Informatics University of.

1 Other Issues for Statisticians in Medical Devices Gregory Campbell, Ph.D. Director, Division of Biostatistics Center for Devices and Radiological Health,

An Update on FDA’s Critical Path Initiative Statistical Contributions

Roseann White Clin/Reg Felllow Abbott Vascular – Cardiac Therapies

Target Product Profile and technical requirements Pre-tender Meeting Pneumococcal Vaccines under the AMC Unicef Supply Division, Copenhagen 26 August.

Assumptions underlying regression analysis

STATISTICAL INFERENCE ABOUT MEANS AND PROPORTIONS WITH TWO POPULATIONS

Chapter 4: Basic Estimation Techniques

Duration of Serum Antibody Response to Seasonal Influenza Vaccines: Summary The level of antibody response made to seasonal influenza vaccines depends.

A ggrastat- Phase of the AGGRASTAT to ZOCOR (A to Z) Trial Comparison of the safety and efficacy of unfractionated heparin versus enoxaparin in combination.

T. A. LouisTrialNet Workshop March 7, The POPPI 1 Example: Statistical Comments Thomas A. Louis, PhD Department of Biostatistics Johns Hopkins Bloomberg.

Unit 4 – Inference from Data: Principles

HPV-vaccines – a breakthrough in medicine Björn Strander Onkologiskt centrum Västra regionen and Kungsbacka Närsjukhus Sweden.

A Flexible Two Stage Design in Active Control Non-inferiority Trials Gang Chen, Yong-Cheng Wang, and George Chi † Division of Biometrics I, CDER, FDA Qing.

Protecting the heart and the kidney: Implications from the SHARP trial Dr. Christina Reith University of Oxford United Kingdom.

Importance of Vaccine Safety Decreases in disease risks and increased attention on vaccine risks Public confidence in vaccine safety is critical Low tolerance.

1 Workshop on the immunological basis of vaccine efficacy Vaccine and Infectious Disease Institute December 14, 2009 Ira M. Longini, Jr. Center for Statistical.

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

Data Mining in VAERS to Enhance Vaccine Safety Monitoring at the FDA

Studying treatment of suicidal ideation & attempts: Designs, Statistical Analysis, and Methodological Considerations Jill M. Harkavy-Friedman, Ph.D.

Licensure of New Pneumococcal Vaccines For Adult Indications

CBER Perspective VRBPAC Meeting, November 16, 2010.

Vaccines and Related Biological Products Advisory Committee Presentation on Sanofi Pasteur’s H5N1 Vaccine Andrea N. James, M.D. Senior Medical Officer.

Vaccine Safety Epidemiology and Prevention of Vaccine- Preventable Diseases National Immunization Program Centers for Disease Control and Prevention Revised.

Viral Hepatitis - Historical Perspective A “Infectious” “Serum” Viral hepatitis Entericallytransmitted Parenterallytransmitted F, G, ? other E NANB BD.

Faculty Research Interest Seminar Series Graduate School of Public Health, UNIVERSITY of PITTSBURGH Methodological Research and Collaboration Lan Kong.

Meningococcal A,C,Y,W135 Conjugate Vaccine (Menactra TM ) Lucia H. Lee CBER, FDA Vaccines and Related Biological Products Advisory Committee Meeting September.

DEVELOPING EVIDENCE ON VACCINE SAFETY Susan S. Ellenberg, Ph.D. Center for Clinical Epidemiology and Biostatistics U Penn School of Medicine Global Vaccines.

Chapter 4 – Research Methods in Clinical Psych Copyright © 2014 John Wiley & Sons, Inc. All rights reserved.

What is a non-inferiority trial, and what particular challenges do such trials present? Andrew Nunn MRC Clinical Trials Unit 20th February 2012.

Effectiveness of Sub-capsular Meningococcal Vaccines An Approach to Evaluate Vaccines for the Prevention of Invasive Group B Meningococcal Disease VRBPAC.

1 Vaccines and Related Biologic Products Advisory Committee (VRBPAC) May 16, 2007 FluMist ® Influenza Virus Vaccine Live, Intranasal Safety and Effectiveness.

VRBPAC Topic #2: Clinical Development of Influenza Vaccines for Pre-pandemic Use Joseph G. Toerner, MD, MPH VCTB/DVRPA/OVRR/CBER/FDA February 27, 2007.

Pathway to Licensure for Protective Antigen-based Anthrax Vaccines for a Post-exposure Prophylaxis Indication Using the Animal Rule.

Zometa for Patients with Bone Metastases Overview and Review of Study 010 Grant Williams, M.D. Medical Team Leader Division of Oncology Drug Products.

1 Study Design Issues and Considerations in HUS Trials Yan Wang, Ph.D. Statistical Reviewer Division of Biometrics IV OB/OTS/CDER/FDA April 12, 2007.

Primary Immunogenicity Endpoints for New Infant Pneumococcal Conjugate Vaccines Vaccines and Related Biological Products Advisory Committee Meeting Lucia.

© Guidant 2005 Surrogate Endpoints and Non-randomized Trials Roseann White Humble Biostatistician.

John W. Tukey’s Multiple Contributions to Statistics at Merck Joseph F. Heyse Merck Research Laboratories Third International Conference on Multiple Comparisons.

1 IMMUNE CORRELATES OF PROTECTION AGAINST INFLUENZA A VIRUSES IN SUPPORT OF PANDEMIC VACCINE DEVELOPMENT FDA/NIH/WHO Public Workshop, December 10-11, 2007.

CBER Introduction to license application: Aventis Pasteur license application for Meningococcal (groups A, C, Y, and W135) Polysaccharide Diphtheria Toxoid.

1 Assessment of the Effectiveness of Small Pox Vaccines: Immunogenicity Assay Considerations Freyja Lynn Division of Bacterial, Parasitic and Allergenic.

Statistical Criteria for Establishing Safety and Efficacy of Allergenic Products Tammy Massie, PhD Mathematical Statistician Team Leader Bacterial, Parasitic.

WHY YOU SHOULD VACCINATE YOUR CHILDREN BY DANA KOISHOR.

1 13-valent pneumococcal conjugate vaccine (PCV13) – new ACIP recommendations 44 th National Immunization Conference April 21, 2010 Pekka Nuorti, MD, DSc.

Remaining Challenges in Assessing Non-Inferiority Steven Snapinn DIA Statistics Community Virtual Journal Club December 16, 2014 Based on Paper with Qi.

1 Considerations for Licensure of Next Generation Smallpox Vaccines Timothy Nelle, PhD Team Leader, Division of Vaccines and Related Applications Office.

Biostatistics Case Studies 2007

Chapter 4 Research Methods in Clinical Psychology

Vaccines and Related Biological Products Advisory Committee Meeting

Vaccine Efficacy, Effectiveness and Impact

Improving Adverse Drug Reaction Information in Product Labels

Mortality and Antithrombotics: Focus on FAERS Repository

Clinical trial کارازمایی بالینی

? Neutralizing Antibodies: Research pathways in 2013 and beyond

Bridging to Bridges in Vaccine Development: Challenges in Comparing Multi-Serotype Vaccines – Jonathan Hartzel, Merck.

Issues in Hypothesis Testing in the Context of Extrapolation

Research Update: The HPV Vaccines

Effect Modifiers.

A Bayesian Design with Conditional Borrowing of Historical Data in a Rare Disease Setting Peng Sun* July 30, 2019 *Joint work with Ming-Hui Chen, Yiwei.

Presentation transcript:

FDA/Industry Statistics Workshop 2005 Parallel Session 6: Vaccine Trials 10:10 am – 11:30 am, Sept. 16, 2005

Co-Chairs: Jingyee Kou (CBER), William Wang (Merck) Panelists: FDA Statistician: Dale Horne (CBER) Academia Statistician: Lawrence Moulton (Johns Hopkins) Industry Statistician: Joseph Heyse (Merck) FDA Clinician: Douglas Pratt (CBER) Industry Clinician: Jill Hackell (Wyeth)

3 Outline Vaccine Safety (1 topic) Vaccine Efficacy (3 topics) Vaccine Immunogenicity (3 topics) Other (1 topic)

4 Vaccine Safety Topic Trial design for pre-licensure and post-licensure study Large safety trial to detect rare adverse reaction. How rare should the event be in the interest of the public health: e.g., 1/1,000 or 1/10,000? Long term safety trial to evaluate potential events with a long-latency pre-licensure (active reporting) versus post-licensure (voluntarily reporting, e.g VAERS )

5 Vaccine Efficacy Topic 1 Estimation of indirect and total effects of vaccine Simple randomization vs Group randomization How should group randomization be used in vaccine development?

6 Vaccine Efficacy Topic 2 Superiority vs super-superiority Study Hypothesis on Vaccine Efficacy (VE) is H 0 : VE 0 When is it enough for the lower limit 0 of the 95% CI to be 0 or close to 0, and when should it be set higher?

7 Vaccine Efficacy Topic 3 How to evaluate vaccine effect on the incidence (randomized comparison) and severity (non- randomized comparison)? Vaccine might reduce the incidence of disease moderately, while reducing severity of the disease among breakthrough cases How should one assess the vaccine efficacy on both the incidence and the severity?

8 Vaccine Immunogenicity Topic 1 Vaccine approval based only on immunogenicity Vaccine may induce strong immune responses that have not been demonstrated as correlates of protection Under what conditions is it appropriate to approve a vaccine based solely on immunogenicity?

9 Vaccine Immunogenicity Topic 2 Selection of immunologic markers and non-inferiority margins Whats proper methodologies to establish immune responses (e.g, antibody level) as correlates of vaccine efficacy? Regression Analysis Proportion Explained Discriminant Analysis What factors should be considered in choosing delta (e.g. 10% vs 15% percentage difference on sero- response rate)?

10 Vaccine Immunogenicity Topic 3 Immunogenicity evaluation with multiple serotypes Combination vaccine containing multiple serotypes How should one evaluate non-inferiority for all components?

11 Other Topic Accelerated development strategy in vaccine development Critical path initiative for vaccine development How should one apply adaptive designs and Bayesian techniques in vaccine development?